Nekrasov
Arkady V. Nekrasov

Founder of NPO Petrovax Pharm, Professor, Doctor of Chemistry, Winner of Russian State Award

  • Petrovax Pharm is founded
  • Polyoxidonium® and Grippol® are registered
  • Prof. Arkady Nekrasov and his team are awarded the Russian Federation State Prize for Polyoxidonium® and Grippol® development and implementation in the country’s healthcare system.
  • A facility is launched to manufacture APIs, semi-solid and solid dosage forms (tablets) and injectables.
  • Partnership with Solvay Pharma (currently, Abbott).
Pack_Polyoxidoniy_10_tablet.jpgIn 2002 the development team headed by Professor A. Nekrasov was awarded the State Prize of the Russian Federation for creation and implementation of Polyoxidonium and Grippol in the healthcare practice.
  • Longidaze® is launched to the market.
  • A state-of-the-art GMP-compliant manufacturing and warehousing complex is put in operation in Pokrov (Podolsk District, Moscow Region).
  • Launch of a unique pre-filled syringe line.
  • Grippol® Pluspreservative-free innovative influenza vaccine is launched to the market.
  • Development and manufacturing of the A/H1N1 pandemic influenza vaccines MonoGrippol Neo, MonoGrippol Plus, and MonoGrippol.
  • The WHO approves Azoximer bromide as the INN for Polyoxidonium®.
  • Grippol® plus vaccine manufacturing for the National Immunization Schedule.
  • Partnership with Pfizer to localize production of a 13-valent pneumococcal conjugate vaccine (including vaccine manufacturing and registration). This project received a Russian Platinum Ounce award.
  • Polyoxidonium®Vet Solution is registered for veterinary use.
  • EU GMP audit successful completion.
  • NPO Petrovax Pharm controlling interest is acquired by Interros Group owner and founder Vladimir Potanin’s company.
  • Agreements are signed on Grippol Plus flu vaccine manufacturinglocalization in the Republic of Belarus and Iran.
  • Imoferaza®, an innovative special care cosmetic cream for post-trauma, post-surgical and post-acne scars is launched to the market.
  • The WHO approves bovhyaluronidase azoximer as the INN for Longidaze®.
  • The Russian Ministry of Health licenses Petrovax Pharm to manufacture Grippol® Plus, a Russian influenza vaccine, using flu antigens produced by St. Petersburg Research Institute for Vaccines and Sera of Russia’s Federal Medical and Biological Agency.
  • Partnership with Boehringer Ingelheim to localize a full-cycle manufacturing of the most advanced cardiovascular pharmaceutical products. The first commercial Metalyse® batches are produced.
  • Polyoxidonium® is a two-time winner of the Russian Pharma Awards (2016 and 2017). Polyoxidonium® tablets label is extended to include children aged 3+ years. A Post-Authorization Safety Study (PASS) for Polyoxidonium® is successfully completed in Europe (Slovakia).
  • Petrovax Pharm is announced the winner of the All-Russia Contest «Russian Business Leaders: Performance and Commitment’2017» in the category «For the Dynamic Development of Business».
  • Grippol® Quadrivalent registration dossier is submitted for review and approval.

grippol_1.png

  • Grippol® Quadrivalent, the first in Russia 4-valent influenza vaccine, launched to the market.
  • NPO Petrovax Pharm manufacturing complex marked its 10-year anniversary; the 3rd production line for API, tablets, and suppositories presented.
  • The latest stage of a joint project with Boehringer Ingelheim to localize production of innovative thrombolytics in Russia completed. 
  • Petrovax Pharm’s products won the 7th Russian Pharma Awards contest: Polyoxidonium® - in the category ‘The Medication of Choice for ARVI and influenza prevention in children’; Longidaze® - in the category ‘The Medication of Choice for pathogenetic treatment of chronic prostatitis and relapse prevention’.
  • NPO Petrovax Pharm won the National Import Substitution Award ‘PRIORITY-2018’ for Grippol® Quadrivalent vaccine.
 1.png